Compare DUOT & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | UNCY |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.9M | 145.3M |
| IPO Year | 2017 | 2021 |
| Metric | DUOT | UNCY |
|---|---|---|
| Price | $8.16 | $6.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $14.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 546.9K | 520.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.96 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,023,651.00 | $675,000.00 |
| Revenue This Year | $50.98 | N/A |
| Revenue Next Year | N/A | $407.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 271.16 | N/A |
| 52 Week Low | $5.39 | $0.47 |
| 52 Week High | $12.17 | $7.57 |
| Indicator | DUOT | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 61.02 | 54.67 |
| Support Level | $7.99 | $5.95 |
| Resistance Level | $8.38 | $7.12 |
| Average True Range (ATR) | 0.52 | 0.41 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 97.55 | 63.44 |
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.